IN8bio to Present at Biotech Showcase 2025 in San Francisco
Rhea-AI Summary
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in Biotech Showcase 2025 in San Francisco. CEO and co-founder William Ho will participate in two key events:
1. A panel discussion on 'The Battle Against Cancer: The Armamentarium Keeps Expanding' on Monday, January 13, 2025, at 8:00 AM PT
2. A corporate presentation on Tuesday, January 14, 2025, at 2:00 PM PT
Both events will take place at the Hilton San Francisco Union Square Hotel. The company's management will also be available for investor meetings from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference. A live webcast of the presentation will be available, and interested parties can register for the event through the provided links.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, INAB gained 19.42%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Showcase 2025 on a panel on Monday, January 13, 2025, and present on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Details for the event are provided below.
Biotech Showcase, January 13 - 15, 2025
Panel: The Battle Against Cancer: The Armamentarium Keeps Expanding
- Date: Monday, January 13, 2025
- Time: 8:00 AM PT
- Track: Yosemite C (Ballroom Level)
Corporate presentation
- Date: Tuesday, January 14, 2025
- Time: 2:00 PM PT
- Track: Yosemite A (Ballroom Level)
- Live webcast: https://event.webcasts.com/starthere.jsp?ei=1703689&tp_key=9d7f185675
Interested parties can register to attend the event here: https://informaconnect.com/biotech-showcase/registration-options/
Additionally, IN8bio management will be in San Francisco from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference and will be available for meetings with investors. Individuals interested in meeting with IN8bio management can contact gdschulman@in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@in8bio.com
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When and where will IN8bio (INAB) present at Biotech Showcase 2025?
What panel will IN8bio's CEO participate in at Biotech Showcase 2025?
How can investors meet with IN8bio management during the J.P. Morgan Healthcare Conference?
Where can I watch the live webcast of IN8bio's Biotech Showcase 2025 presentation?
How can I register to attend IN8bio's presentation at Biotech Showcase 2025?
